About us
Facts
-
80
Million units of production per year
-
65+
Pharmaceutical products across various ATC groups
-
60
Years of stable development and growth
PJSC «Kraspharma»
A multi-tiered, high-tech enterprise, a complex mechanism driven by a single goal - the production of competitive pharmaceutical products capable of providing the appropriate therapeutic effect with a minimum risk of adverse reactions.
Our Mission
Our mission is to satisfy the growing healthcare needs for high-quality, effective, and safe medications, with constant quality control, development, and production of innovative pharmaceutical products.
Our Values
-
Responsibility
We have taken on the responsibility of preserving people's lives, and every person saved thanks to our products is another victory. This is what allows us to move forward, gives us the impetus and energy to develop and improve on our path.
-
Partnership
We recognize mutually beneficial cooperation in the spirit of "WIN-WIN". In building relationships with our partners, we adhere to the principles of long-term cooperation, mutual respect, and willingness to engage in objective dialogue. Only this type of cooperation helps us fulfill our mission.
-
Professionalism
A team with a high level of professionalism is a guarantee of the high quality of our products; their availability to the general public; as well as a guarantee of the search and implementation of innovative products necessary to preserve and improve the quality of life of patients.
Company history
The company "Kraspharma" was at the forefront of creating the modern domestic pharmaceutical industry. Over more than half a century of productive work, the company has proven its viability: consistently high product quality, the ability to adapt to the new economic pharmacy, and continuous improvement through the implementation of good manufacturing practice standards.
Key dates
-
The Founding Year of Kraspharma Pharmaceutical Plant. The history of Kraspharma Pharmaceutical Plant officially began in 1959, when production was launched at the new facility with two distinct technological streams: one dedicated to penicillin manufacturing and the other to streptomycin production. In the same year, the state commission approved the commissioning of the first-phase main production building, which housed the fermentation and chemical purification workshops for penicillin. The first industrial batch of 800 grams of "Krasnoyarsk Penicillin" was produced on-site.1959
-
The enterprise experienced rapid growth. In 1961, the state commission approved the permanent operation of the main streptomycin production building, which included fermentation and chemical purification workshops.1961
-
Just six years after its establishment, the plant reached its designed production capacity and commenced product exports to multiple international markets.1965
-
To meet the increasing healthcare demands, the company expanded its operations over the next two years by launching the third production phase for dextran-based pharmaceuticals and injectable solutions, followed by the fourth phase dedicated to infusion solutions manufacturing.1966 - 1969
-
In 1983, with the approval of the USSR government, the plant received the status of a pharmaceutical complex due to its broad product portfolio and was renamed «Krasnoyarskmedpreparaty Complex».
1983 -
During the 1990s, the management prioritized the integration of cutting-edge scientific advancements, continued process optimization, and the search for innovative raw materials and components. The manufacturing process was enhanced through the adoption of high-yield microbial strains, new fermentation media, and extensive mechanization and automation of production workflows.1990s
-
In 1993, the enterprise underwent corporatization and, as of June 3, was transformed into a Public Joint-Stock Company (PJSC) Kraspharma. This marked a new stage in its development, leading to portfolio expansion and increased production volumes.1993
-
Despite the global economic crisis, Russia’s financial default, and overall economic downturn, PJSC Kraspharma maintained its leadership in the hospital pharmaceutical segment, offering 30 high-demand products:
- 6 antibiotic formulations
-
24 types of blood substitutes and infusion solutions
1999 -
In 2000, PJSC Kraspharma became part of the domestic pharmaceutical holding PJSC Valenta Pharmaceuticals (formerly PJSC National Medicines).2000
-
PJSC Kraspharma expanded its hospital pharmaceutical portfolio by introducing parenteral antibiotics essential for the healthcare sector. By 2004, the company was producing 34 pharmaceutical products:
- 17 antibacterial formulations
-
17 blood substitutes and infusion solutions
2004 -
The company continued upgrading its infrastructure, implementing advanced technological processes, and developing new pharmaceutical products. These improvements enhanced product quality and expanded market reach. During this period, PJSC Kraspharma achieved its best financial performance in history, with total production output reaching 1.852 billion rubles.
In 2007, PJSC Kraspharma manufactured:
-
16 antibiotic formulations
-
22 types of blood substitutes and injectable solutions
-
Gramicidin
2005 – 2007 -
-
Amid the global financial crisis of 2008, Valenta Pharmaceuticals was compelled to sell its controlling stake in PJSC Kraspharma.
The new management developed a strategic stabilization program, implementing anti-crisis measures to ensure the sustainability of this critical pharmaceutical enterprise. Within 12–18 months, these efforts aimed to establish a high-tech, profitable pharmaceutical production facility in Krasnoyarsk and enhance product competitiveness.
2008 -
In line with its development strategy, PJSC Kraspharma continues the phased modernization of its production facilities.
Cleanroom environments are being reconstructed, expanded, and upgraded; engineering and control systems — including ventilation, air conditioning, and monitoring — are being modernized with the implementation of advanced digital management technologies. Air supplied to cleanrooms is treated using high-efficiency HEPA filtration systems. Key upgrades have been completed for sterilization and cleaning systems, clean steam generation, as well as purified water and water-for-injection systems.
PJSC «Kraspharma» maintains strategic partnerships with leading API manufacturers from Asia and Europe. Regular audits of suppliers of active pharmaceutical ingredients and primary packaging materials are conducted to ensure the quality and efficacy of finished products.
Pharmacovigilance is a core part of our operations, with an established monitoring system ensuring the continued safety of the medicines we produce.2010 -
In line with its development strategy, PJSC Kraspharma has completed a phased modernization of its production facilities. Cleanrooms have undergone major reconstruction, expansion, and technological enhancement. Engineering and control systems — including ventilation, air conditioning, and monitoring — have been overhauled or newly installed, with a full transition to digital control platforms.
Air supplied to cleanrooms is treated using high-efficiency HEPA filtration systems. The company has also upgraded its equipment cleaning and sterilization systems, as well as systems for clean steam generation, purified water, and water for injection.2011–2014 -
Pharmacovigilance for the company’s medicinal products is ensured through a dedicated pharmacovigilance system, which was reorganized into an independent functional unit.
A state-of-the-art warehouse complex was constructed, while the central laboratory was fully renovated and equipped with the latest analytical instrumentation. Essentially, the manufacturing site underwent a complete transformation—no pharmaceutical enterprise in Russia had previously undergone such an extensive and comprehensive modernization.
2015–2016 -
PJSC **Kraspharma** established strategic partnerships with major API manufacturers from Asia and Europe. Regular audits of active pharmaceutical ingredient (API) suppliers and primary packaging material vendors are conducted to ensure the quality and efficacy of the company’s pharmaceutical products.
The product portfolio was expanded with new drugs across various ATC groups, with a strong focus on developing antimicrobial agents targeting infections caused by multidrug-resistant pathogens. Additionally, the company actively supports the national policy of import substitution for high-tech pharmaceutical products.
With its longstanding commitment to quality and affordability, PJSC «Kraspharma» has reinforced its position as a leading manufacturer of hospital-sector pharmaceuticals.2017 -
From Modernization to Expansion
In response to the growing product portfolio of pharmaceuticals produced by PJSC "Kraspharma," increased sales across the Russian Federation, CIS countries, and international markets, as well as evolving regulatory requirements set by the EEC for healthcare-related manufacturing, the company has made the strategic decision to construct a new, state-of-the-art production facility.
This new site is designed in full compliance with stringent industry standards, incorporating cleanroom environments, advanced equipment, rigorous personnel protocols, and other cutting-edge technologies and methodologies.
Our R&D division continues to grow rapidly, with ongoing development of new treatments targeting infections caused by resistant pathogens.2018 -
Kraspharma’s key pharmaceutical products — Fosfomycin, Sabvixin, Bactefort, Orthocid, and Ingastin — are integrated into treatment protocols for some of the most severe and complex infectious and inflammatory diseases, consistently demonstrating high clinical and microbiological efficacy.
During the COVID-19 pandemic, Kraspharma's medicines, included in the official treatment standards for complications of this life-threatening infection, played a vital role in saving hundreds of lives. The company ensured an uninterrupted supply of essential and critical medications to meet the urgent needs of the national healthcare system.2019– 2022 -
Continuous Growth and Modernization
Kraspharma is actively evolving and expanding. The Krasnoyarsk manufacturing site of PJSC «Kraspharma» is more than just a pharmaceutical production facility — it is the only enterprise of its kind in the Krasnoyarsk Territory and serves as a key driver of scientific progress and regional economic development. The strategic importance of Kraspharma as a producer of essential medicines has been officially recognized by regional authorities. The significant advancements the company has made over the past two decades have received high praise. Research and development efforts remain a top priority. Current projects include the development of treatments for infections caused by fungal pathogens — a particularly urgent issue among immunocompromised patients — as well as anti-inflammatory drugs and the discovery of new molecules for pathogenetic therapy and organ protection in critical care settings.2022 –present
Natalia Novikova
CEO PJSC «Kraspharma»
Honesty, integrity, and high business standards remain the core principles on which we continue to build the new company ‘Kraspharma’. As always, our mission is to provide innovative pharmaceutical products aimed at preserving and improving the quality of life.
Full statement
PJSC «Kraspharma» is the largest Russian chemical-pharmaceutical manufacturing company, creating pharmaceutical products that meet national and international quality standards for more than 65 years.
PJSC «Kraspharma» is among the largest producers of high-tech chemical-pharmaceutical products in Russia and specializes in the production, storage, and distribution of pharmaceuticals, most of which are included in the national list of Essential and Vital Drugs (EVD).
PJSC «Kraspharma» is among the largest producers of high-tech chemical-pharmaceutical products in Russia and specializes in the production, storage, and distribution of pharmaceuticals, most of which are included in the national list of Essential and Vital Drugs (EVD).
The implementation and maintenance of pharmaceutical production in accordance with the GMP standard is impossible without addressing staffing issues. Therefore, the main value of PJSC "Kraspharma" is its people. Currently, the company employs about 600 people. Despite the challenges related to changes in the social structure of society and financial crises, the company has retained a trained workforce capable of servicing complex production equipment and mastering the production of new drugs.
PJSC «Kraspharma» is an undisputed expert in ensuring the quality of its manufactured medicinal products, and as a result, the company's products have earned a high reputation in the market and within the medical community. We produce pharmaceutical products of exceptionally high clinical value, which are in demand for providing qualified medical care to both adults and children. Therefore, all aspects of quality are subject to stringent control.
-
We are a team of dedicated and inspired professionals, driven by results and committed to excellence in everything we do. Our shared motivation fuels innovation, collaboration, and long-term success.
-
We challenge every member of our team to look ahead and consistently exceed the expectations of those who rely on our products.
-
Our manufacturing environment is designed to meet the highest standards — and we are committed to its continuous improvement.
-
Integrity, conscientiousness, and professionalism — these are the qualities we expect from every member of our team.
-
We are committed to maintaining financial performance that meets the expectations of our shareholders.
Company management
-
Natalia Viktorovna NovikovaCEO
-
Andrei Sergeevich OsipenkoChief Technical Officer (CTO)
-
Sergey Vladimirovich EvdokimovDeputy CEO for General Affairs
-
Dmitry Mikhailovich NovoselovFinancial Director
-
Vera Sergeevna MalyaevaCommercial Director
-
Olga Mikhailovna RashupkinaDeputy CEO for Production and Development
-
Natalia Vladimirovna NikitasenkoDeputy CEO for Quality
-
Evgeny Nikolaevich SychevHead of Pharmacovigilance Department
-
Marina Kirillovna TverdovaDeputy General Director for Legal Affairs
-
Tatiana Garaftynovna EgorovaHR Director
-
Olga Grigoryevna SundukovaDeputy CEO for Logistics
-
Boris Vladimirovich ShkolnikovHead of Foreign Trade Sales Department
